Immunotherapy of metastatic kidney cance
โ
Giancarlo Pizza; Caterina De Vinci; Giuseppe Lo Conte; Paolo Maver; Ennio Dragon
๐
Article
๐
2001
๐
John Wiley and Sons
๐
French
โ 337 KB
122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 ุ 10 6 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy